Search alternatives:
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), i non (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 non » _ non (Expand Search), a non (Expand Search), i non (Expand Search)
-
461
-
462
-
463
HRMECs treated with SUZ12 siRNA demonstrate increased miR-200b expression, decreased VEGF expression and decreased endothelial branching.
Published 2015“…However, transfection of SUZ12 siRNA significantly reduced endothelial branching compared to HG+control siRNA. [NG+control siRNA = 5mM D-glucose + 100nM control siRNA, HG+control siRNA = 25mM D-glucose + 100nM control siRNA, HG+EZH2 siRNA = 25mM D-glucose + 100nM EZH2 siRNA, HG+SUZ12 siRNA = 25mM + 100nM SUZ12 siRNA; identical letters represent groups that are not significantly different; p < 0.05; n = 6; data expressed as mean ± SEM, normalized to U6 or β-actin and expressed as a fold change of NG+control siRNA].…”
-
464
Delphinidin alters VEGF-A splicing to increase VEGF-A<sub>165</sub>b and decrease total VEGF-A expression.
Published 2019“…<p><b>A)</b> Treatment of podocytes with delphinidin chloride (10 μg/ml) under normal glucose (NG; 5 mM glucose + 25 mM mannitol) and high glucose (HG; 30 mM glucose, 1 ng/ml TNFα, 1 ng/ml IL-6, and 100 nM insulin) for 48 hrs increased the protein expression of VEGF-A<sub>165</sub>b relative to total VEGF-A<sub>165</sub> (quantified in <b>B</b>; *p<0.05 vs NG, †p<0.05 vs HG; n = 3 biological repeats; One-way ANOVA with Bonferroni post-hoc test for comparison between pairs; <b>A</b>—the same blot was first probed with VEGF-A<sub>165</sub>b before stripping and reprobing with panVEGF-A). …”
-
465
-
466
-
467
Relationships between empty body lipid weight decrease and corrected amounts of pollutants excreted through faeces (faecal output–feed input) for TCDD (○, ●), and PCBs 153 (□, ■) and 126 (Δ, ▲) over a 57-day depuration period in ewes receiving a control well-fed and non-supplemented treatments (CTL: ○, □, Δ; <i>n</i> = 4), or an underfed and mineral oil supplemented treatment (UFMO: ●, ■, ▲; <i>n</i> = 5).
Published 2020“…<p>Relationships between empty body lipid weight decrease and corrected amounts of pollutants excreted through faeces (faecal output–feed input) for TCDD (○, ●), and PCBs 153 (□, ■) and 126 (Δ, ▲) over a 57-day depuration period in ewes receiving a control well-fed and non-supplemented treatments (CTL: ○, □, Δ; <i>n</i> = 4), or an underfed and mineral oil supplemented treatment (UFMO: ●, ■, ▲; <i>n</i> = 5).…”
-
468
-
469
-
470
-
471
-
472
-
473
-
474
-
475
-
476
-
477
Functional characterization of the V9D and R10C substitutions in chicken ARF.
Published 2017“…Spectra of all peptides in free form and at 25 μM concentration in complex with MDM2<sub>204-298</sub> are shown in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1006665#pgen.1006665.s008" target="_blank">S5 Fig</a>. …”
-
478
-
479
Antagonizing BMP type I receptors decreases cell growth, proliferation, and clonogenicity of lung cancer cell lines.
Published 2013“…<p>(<b>A</b>) A549 and H1299 cells cultured in DMEM 5% FCS were treated with DMSO, 10 µM Dorsomorphin, 1 µM DMH1, 1 µM DMH2, or 1 µM LDN for 7 days and cell counts performed. …”
-
480